2011
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells
Cheng B, Ling C, Dai Y, Lu Y, Glushakova L, Gee S, McGoogan K, Aslanidi G, Park M, Stacpoole P, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy 2011, 19: 375-384. PMID: 21776025, PMCID: PMC3519243, DOI: 10.1038/gt.2011.105.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCarcinoma, HepatocellularCell Line, TumorDependovirusFemaleGenetic VectorsHumansLiver NeoplasmsMiceMutagenesis, Site-DirectedProteasome InhibitorsProtein Structure, TertiaryProto-Oncogene Proteins c-metTransduction, GeneticTransplantation, HeterologousTyrosineVirus IntegrationConceptsHigh-efficiency transductionAAV3 vectorsTransduction efficiencySerotype vectorsSurface-exposed tyrosinePotential gene therapyHuman hepatocyte growth factor receptorHuman liver cancer cellsGene therapyLiver cancer cellsTransgene expressionVector entryAAV3 capsidsDirect intratumoral injectionAAV3Tail vein injectionLiver tumor cellsIntratumoral injectionCancer cellsEfficiencyAdenoVectorIntracellular kinase domainVirus serotypes
2005
Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid -Glucosidase in a Model of Glycogen Storage Disease Type II
Cresawn K, Fraites T, Wasserfall C, Atkinson M, Lewis M, Porvasnik S, Liu C, Mah C, Byrne B. Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid -Glucosidase in a Model of Glycogen Storage Disease Type II. Human Gene Therapy 2005, 16: 68-80. PMID: 15703490, DOI: 10.1089/hum.2005.16.68.Peer-Reviewed Original ResearchConceptsGlycogen storage disease type IIImmune-tolerant miceStorage disease type IIAntibody responseContractile functionImmune responseHumoral immune responseHind limb musclesAcid alpha-glucosidaseCardiorespiratory failureType IIAntibody formationReduced glycogenGlycogen reductionLysosomal storage diseaseSoleus muscleGAA levelsMiceEnzyme levelsSkeletal muscleStorage diseaseLevel of activityMuscleRecombinant adenoAlpha-glucosidase
1991
Characterization of the core promoter and enhancer of duck hepatitis B virus
Liu C, Condreay L, Burch J, Mason W. Characterization of the core promoter and enhancer of duck hepatitis B virus. Virology 1991, 184: 242-252. PMID: 1871970, DOI: 10.1016/0042-6822(91)90841-x.Peer-Reviewed Original Research